CSBR on Nasdaq

Champions Oncology

Logo: https://www.championsoncology.com/, Non-free logo, via Wikipedia5

American technology company

Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

$59.4MRevenue, fiscal 20266
-$1.2MNet income, fiscal 20266
2001Founded1

Compare with Invivyd, Inc., Protalix Biotherapeutics Inc or VIR Biotechnology, or pick any stock.

  • TickerCSBR on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersHackensack1
  • Websitechampionsoncology.com
  • Incorporated inDE7
  • Business address855 N. Wolfe Street, Suite 619, Baltimore, Md 212057
  • Filer categoryNon-accelerated filer, Smaller reporting company7
  • Legal formCorporation4
  • LEI549300O8WKLP8QEG5U474
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4

See how the biggest companies compare on our leaderboards

Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-1.9%Operating margin6
-2.0%Net margin6
4.4%Revenue growth, 20266
-29.8%Return on equity6
-$5.0MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Pharmacology Services brought in 96% of the revenue Champions Oncology broke down this way in fiscal 2026.

  1. Pharmacology Services$57.1M696%up 18% from 2025
  2. Product and Service, Other$1.5M63%down 59% from 2025
  3. Translational Oncology Solutions (TOS) License Revenue$764.0K61%down 84% from 2025
Products and services by year
Products and services20252026
Pharmacology Services$48.6M$57.1M
Product and Service, Other$3.7M$1.5M
Translational Oncology Solutions (TOS) License Revenue$4.7M$764.0K

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue52¢$30.9M
  • Research and development15¢$9.1M
  • Other costs32¢$19.2M
  • Income tax0¢$246.0K

Out of $59.4M in revenue.6 The company lost money this year.

Financial statements

Revenue89101112136$59.4M in 2026+120% since 2019
0$20.0M$40.0M$60.0M2019: $27.1M$27.1M20192020: $32.1M$32.1M2020+19%2021: $41.0M$41.0M2021+28%2022: $49.1M$49.1M2022+20%2023: $53.9M$53.9M2023+10%2024: $50.2M$50.2M2024−7%2025: $56.9M$56.9M2025+14%2026: $59.4M$59.4M2026+4%
Operating income89101112136-$1.1M in 2026
-$10.0M-$5.0M0$5.0M2019: $270.0K$270.0K20192020: -$1.9M-$1.9M20202021: $366.0K$366.0K20212022: $607.0K$607.0K2022+66%2023: -$5.3M-$5.3M20232024: -$7.4M-$7.4M2024+40%2025: $4.6M$4.6M20252026: -$1.1M-$1.1M2026
Net income89101112136-$1.2M in 2026
-$10.0M-$5.0M0$5.0M2019: $128.0K$128.0K20192020: -$2.1M-$2.1M20202021: $362.0K$362.0K20212022: $548.0K$548.0K2022+51%2023: -$5.3M-$5.3M20232024: -$7.3M-$7.3M2024+36%2025: $4.7M$4.7M20252026: -$1.2M-$1.2M2026

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2026-04-302025-04-30
Oncology revenue$59.4M$56.9M
Cost of oncology revenue$30.9M$28.4M
Research and development$9.1M$6.8M
Sales and marketing$9.3M$7.5M
General and administrative$11.2M$9.3M
Loss on disposal of equipment$111.0K$293.0K
Total costs and operating expenses$60.6M$52.4M
Income (loss) from operations-$1.1M$4.6M
Other income, net$211.0K$73.0K
Income (loss) before income tax expense-$929.0K$4.6M
Provision (benefit) for income tax$246.0K-$75.0K
Net income (loss)-$1.2M$4.7M
basic (in dollars per share)-$0.08$0.34
diluted (in dollars per share)-$0.08$0.33
basic (in shares)13.8M shares13.7M shares
diluted (in shares)13.8M shares14.3M shares

Compare Champions Oncology with another company

Leadership

Who has led Champions Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joel Ackerman2010–2016
  2. Ronnie Morris2018–2023
  3. Robert Lawrence Brainin2026–now

Chair

  1. David Sidransky2009

President

  1. Douglas D. Burkett2008
  2. Ronnie Morris2010–2016
  3. Brady Davis2024

Chief financial officer

  1. Mark Schonau2009–2010
20052010201520202025
Board members and other officers (12)

Former names

  • CHAMPIONS BIOTECHNOLOGY, INC.Mar 19, 2007 to Mar 30, 20117
  • CHAMPIONS SPORTS INCSep 13, 1995 to Feb 16, 20077

Timeline

  1. Jan 30, 2026New chief executive Robert Lawrence Brainin becomes CEO18
  2. Mar 26, 2018New chief executive Ronnie Morris becomes CEO19
  3. Oct 29, 2010New chief executive Joel Ackerman becomes CEO20
  4. 2001Founded Founded1

Filings

135 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 30 major events, 65 insider forms, 5 large holders, 15 other. The latest 20:

  1. Sep 11, 202610-Q EDGAR
  2. Sep 10, 20268-K EDGAR
  3. Aug 28, 2026DEFA14A EDGAR
  4. Aug 28, 2026DEF 14A EDGAR
  5. Jul 27, 202610-K EDGAR
  6. Jul 27, 20268-K EDGAR
  7. Mar 30, 20268-K EDGAR
  8. Mar 12, 202610-Q EDGAR
  9. Mar 12, 20268-K EDGAR
  10. Jan 30, 20264 EDGAR
  11. Jan 30, 20264 EDGAR
  12. Jan 16, 20263 EDGAR
  13. Dec 15, 202510-Q EDGAR
  14. Dec 15, 20258-K EDGAR
  15. Nov 7, 20254 EDGAR
  16. Nov 7, 20254 EDGAR
  17. Nov 7, 20254 EDGAR
  18. Nov 7, 20254 EDGAR
  19. Nov 7, 20254 EDGAR
  20. Nov 6, 20254 EDGAR

The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 26 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 12, 2024Mendelson Daniel NewmanDirectorBuy1,000$6.50$6.5KForm 4
Jan 11, 2024Mendelson Daniel NewmanDirectorBuy2,000$6.27$12.5KForm 4
Jan 10, 2024Mendelson Daniel NewmanDirectorBuy2,944$6.31$18.6KForm 4
Jan 9, 2024Mendelson Daniel NewmanDirectorBuy3,000$6.25$18.8KForm 4
Jan 8, 2024Mendelson Daniel NewmanDirectorBuy1,000$6.15$6.2KForm 4
Jan 5, 2024Mendelson Daniel NewmanDirectorBuy2,000$6.09$12.2KForm 4
Jan 4, 2024Mendelson Daniel NewmanDirectorBuy3,000$6.12$18.4KForm 4
Jan 3, 2024Mendelson Daniel NewmanDirectorBuy500$5.83$2.9KForm 4
Dec 21, 2023Mendelson Daniel NewmanDirectorBuy2,500$4.92$12.3KForm 4
Dec 20, 2023Mendelson Daniel NewmanDirectorBuy2,100$4.82$10.1KForm 4
Dec 19, 2023Mendelson Daniel NewmanDirectorBuy5,000$4.75$23.8KForm 4
Oct 11, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.40$32.0KForm 4
Oct 10, 2023Mendelson Daniel NewmanDirectorBuy1,100$6.41$7.1KForm 4
Oct 6, 2023Mendelson Daniel NewmanDirectorBuy1,530$6.48$9.9KForm 4
Oct 5, 2023Mendelson Daniel NewmanDirectorBuy2,000$6.47$12.9KForm 4
Oct 4, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.40$32.0KForm 4
Oct 3, 2023Mendelson Daniel NewmanDirectorBuy2,500$6.30$15.8KForm 4
Sep 29, 2023Mendelson Daniel NewmanDirectorBuy4,000$6.16$24.6KForm 4
Sep 28, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.22$31.1KForm 4
Sep 27, 2023Mendelson Daniel NewmanDirectorBuy1,500$5.95$8.9KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Battery Management Corp.2,421,673$14.9M4.1%No change
NEA Management Company, LLC1,713,720$10.6M0.7%No change
Vanguard Capital Management LLC301,353$1.9M0.0%+1,833
Tocqueville Asset Management L.P.295,658$1.8M0.0%−24,016
Morgan Stanley235,400$1.5M0.0%−6,900
Bank Of America Corp /de/214,058$1.3M0.0%+192,225
Renaissance Technologies LLC139,039$856.5K0.0%−6,500
BlackRock, Inc.129,848$799.9K0.0%+5,948
Mink Brook Asset Management LLC111,338$685.8K0.3%No change
Geode Capital Management, LLC76,300$470.1K0.0%−877
HighTower Advisors, LLC41,901$258.1K0.0%+6,743
Vanguard Fiduciary Trust Co33,239$204.8K0.0%+247
Northern Trust Corp27,910$171.9K0.0%−18,022
State Street Corp26,203$161.4K0.0%No change
Bank of New York Mellon Corp21,614$133.1K0.0%No change
Citadel Advisors LLC18,295$112.7K0.0%New
Essex Investment Management Co LLC18,221$112.2K0.0%−28
Mesirow Financial Investment Management, Inc.15,800$97.3K0.0%No change
Mercer Global Advisors Inc /adv12,775$78.7K0.0%New
Vanguard Global Advisers, LLC2,093$12.9K0.0%No change
Cambridge Investment Research Advisors, Inc.24,504$1500.0%+12,252
Acadian Asset Management LLC20,523$1250.0%−800
Barclays PLC13$800.0%New
Jpmorgan Chase & Co11$710.0%No change
Cassaday & Co Wealth Management LLC10$620.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38